Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Simmons Bank

Simmons Bank lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 90.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,587 shares of the medical research company's stock after selling 35,633 shares during the period. Simmons Bank's holdings in Edwards Lifesciences were worth $237,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Park Avenue Securities LLC grew its stake in shares of Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company's stock worth $2,169,000 after acquiring an additional 108 shares during the period. City State Bank increased its position in Edwards Lifesciences by 16.5% in the second quarter. City State Bank now owns 917 shares of the medical research company's stock worth $85,000 after purchasing an additional 130 shares during the last quarter. Stableford Capital II LLC raised its stake in shares of Edwards Lifesciences by 2.7% in the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company's stock valued at $533,000 after acquiring an additional 159 shares during the period. Purus Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 5.2% in the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company's stock valued at $297,000 after acquiring an additional 160 shares during the period. Finally, Busey Bank increased its stake in Edwards Lifesciences by 1.9% in the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company's stock worth $816,000 after buying an additional 165 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on EW shares. UBS Group cut their target price on shares of Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating on the stock in a research report on Tuesday, September 10th. Wells Fargo & Company lowered their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating for the company in a research note on Monday, September 9th. Bank of America lowered shares of Edwards Lifesciences from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $105.00 to $75.00 in a research report on Thursday, July 25th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on shares of Edwards Lifesciences from $103.00 to $85.00 and set a "buy" rating for the company in a research report on Thursday, July 25th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $75.67.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company's stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,250 shares of company stock worth $2,744,438. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Up 1.6 %

NYSE EW traded up $1.08 during trading hours on Friday, reaching $67.24. The company had a trading volume of 2,552,883 shares, compared to its average volume of 4,620,448. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $39.66 billion, a P/E ratio of 9.58, a price-to-earnings-growth ratio of 3.74 and a beta of 1.12. The stock has a 50-day moving average of $67.42 and a 200 day moving average of $76.37. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.59 earnings per share. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.